22:31:09 Europe / Stockholm

Kurs & Likviditet

Kursutveckling och likviditet under dagen för detta pressmeddelande

Beskrivning

LandDanmark
ListaFirst North Stockholm
SektorHälsovård
IndustriBioteknik
Scandion Oncology är verksamma inom bioteknik. Bolaget utvecklar läkemedel för behandling av cancer som innehåller läkemedelsresistenta cellkloner. Bolagets läkemedelskandidat, SCO-101, har i prekliniska studier använts inom olika standardcancerbehandlingar. Bolaget grundades under 2017 och har sitt huvudkontor i Köpenhamn.

Kalender

2023-02-22 Bokslutskommuniké 2022
2022-11-16 Kvartalsrapport 2022-Q3
2022-08-25 Kvartalsrapport 2022-Q2
2022-05-19 Kvartalsrapport 2022-Q1
2022-04-28 Ordinarie utdelning SCOL 0.00 SEK
2022-04-27 Årsstämma 2022
2022-02-17 Bokslutskommuniké 2021
2021-11-18 Kvartalsrapport 2021-Q3
2021-11-17 Extra Bolagsstämma 2021
2021-08-19 Kvartalsrapport 2021-Q2
2021-05-27 Ordinarie utdelning SCOL 0.00 SEK
2021-05-26 Årsstämma 2021
2021-05-20 Kvartalsrapport 2021-Q1
2021-02-18 Bokslutskommuniké 2020
2020-11-19 Kvartalsrapport 2020-Q3
2020-08-20 Kvartalsrapport 2020-Q2
2020-05-28 Ordinarie utdelning SCOL 0.00 SEK
2020-05-27 Årsstämma 2020
2020-05-21 Kvartalsrapport 2020-Q1
2020-02-20 Bokslutskommuniké 2019
2019-11-21 Kvartalsrapport 2019-Q3
2019-08-22 Kvartalsrapport 2019-Q2
2019-06-11 Extra Bolagsstämma 2019
2019-05-31 Ordinarie utdelning SCOL 0.00 SEK
2019-05-29 Årsstämma 2019
2019-05-27 Kvartalsrapport 2019-Q1
2019-02-21 Bokslutskommuniké 2018
2018-11-18 Kvartalsrapport 2018-Q3
2022-04-12 08:30:00

The board of directors hereby give notice of the annual general meeting in:

Scandion Oncology A/S

CVR-no. 38613391

(the "Company")

Wednesday, April 27, 2022, at 4pm (CET), at the Company's address, Fruebjergvej 3, 2100 Copenhagen, Denmark.

With the following agenda:

1. Election of chairman of the meeting

2. Report from the board of directors on the Company's activities in the past
year

3. Presentation of the audited annual report prepared in English for approval

4. Proposal of notice of discharge to the board of directors and the
executive board

5. Decision on appropriation of profit or loss as recorded in the approved
annual report

6. Proposal of approval of the board of directors' fee for 2022

7. Election of members of the board of directors

8. Election of auditor

9. Proposals resulting in changes to the Company's articles of association

     (a): Proposal to authorize the board of directors to issue warrants and
any related capital     increases(s)

     (b): Proposal to introduce English as corporate language etc.

     (c): Proposal to other amendments of the Company's articles of
association

10.  Any other business

More details to each of the agenda items can be found in schedule 1: Full
wording of the proposals in relation to the Agenda.

Share capital and voting rights of the shareholders

The Company's nominal share capital is DKK 2,361,962.4840, divided into shares
of DKK 0.0735 each or multiples thereof. Each share of the nominal value of
DKK 0.0735 carries one vote. The total number of votes as of the date of this
notice is thus 32,135,544.

Attendance and casting of votes at the general meeting

A shareholder's right to attend the general meeting and to vote on its shares
is determined on the basis of the shares held by the shareholder at the date
of registration.

The date of registration is April 20, 2022 ("Date of Registration").

Only shareholders in the Company as at the Date of Registration have the right
to attend the annual general meeting and vote on its shares.

The shares held by each shareholder at the Date of Registration are calculated
based on the registration of the number of shares held by the shareholder in
the Company's register of shareholders as well as any notification of
ownership received by the Company on or before the Date of Registration for
the purpose of registration in the Company's register of shareholders, but
which as of the Date of Registration had not yet been registered.

Any sale or purchase of shares in the Company taking place after the Date of
Registration and until the date of the general meeting will not affect the
voting rights on the general meeting or any postal votes.

Admission Card, Proxy and Postal Voting

In order to attend the general meeting a shareholder must request an admission
card no later than April 22, 2022, 11.59 p.m. (CET). The request shall be made
to the Company, e-mail: agm@scandiononcology.com.

All shareholders are entitled to attend the general meeting by proxy. If a
shareholder wishes to attend by proxy, the shareholder will need to request an
admission card for the proxy holder as set out above and fill out a written
and dated instrument of proxy. The proxy holder must be able to present the
admission card and the written and dated instrument of proxy at the general
meeting.

Proxies may be submitted in writing by using the written proxy form attached
to this notice as schedule 5 and which can also be found on the Company's
website www.scandiononcology.com. The Company requests that signed forms are
received by the Company at the address Fruebjergvej 3, DK-2100 Copenhagen or
by e-mail to: agm@scandiononcology.comno later than April 25, 2022 at 11.59
p.m. (CET). Proxies received after this date cannot be expected to have been
received at the general meeting.

A shareholder can also choose to make use of postal vote instead of attending
the annual general meeting in person.

Postal votes may be submitted in writing by using the postal voting form
attached to this notice as schedule 5 and which also can be found on the
Company's website www.scandiononcology.com. A completed and signed form must
be received by the Company at the address Fruebjergvej 3, DK-2100 Copenhagen,
or by e-mail to: agm@scandiononcology.comno later than April 25, 2022 at
11.59 p.m. (CET).

Postal votes received by the Company cannot be cancelled or revoked.

Webcast

A live webcast of the general meeting will be available. Shareholders who
webcast the general meeting will have the opportunity to submit written
questions electronically at the general meeting via a chat function.

When webcasting the general meeting, each shareholder is responsible for
ensuring that the shareholder has a mobile phone or a desktop/tablet device
with a web browser and that the shareholder has an adequate and functioning
internet connection available at the time of the general meeting.

Shareholders participating via live webcast of the general meeting, are
encouraged to submit a proxy or vote by post prior to the general meeting.
Please note that it will not be possible to cast votes at the general meeting
in connection with the webcast.

Link to the webcast will be sent to shareholders who have requested such prior
to the general meeting. The request for the webcast link shall be made to the
Company, e-mail: agm@scandiononcology.comno later than April 25, 2022 at
11.59 p.m. (CET).

Schedules

Schedule 1: Full wording of the proposal in relation to the agenda

Schedule 2: Draft articles of association

Schedule 3: Draft new appendix 4.3 to the articles of association

Schedule 4: Information on management positions etc.

Schedule 5: Proxy and postal vote form

This notice is also available in Danish at the Company's website www.scandiononcology.com.

For further information please contact:

Mads Kronborg, Head of External Communication

Phone: +45 6051 4955

E-mail: ir@scandiononcology.com (info@scandiononcology.com)

The information was provided by the contact person above for publication on April 12, 2022, at 08.30 CET.

Scandion Oncology A/S, the Cancer Drug Resistance Company, is a clinical phase II biotechnology company currently developing first-in-class, oral add-on drugs to existing market leading anti-cancer therapies. As add-on to standard anti-cancer therapies, it introduces an effective treatment approach for cancer, which is or has become resistant to cancer-fighting drugs, offering the potential for better response rates, longer survival, and improved quality of life. The first-in-class lead candidate, SCO-101, is currently in clinical phase II. The Company is targeting cancer drug resistance in various treatment modalities including chemotherapy, anti-hormonal therapy and immunotherapy. Scandion Oncology is listed on Nasdaq First North Growth Market Sweden. Ticker: SCOL.

Västra Hamnen Corporate Finance is the Company's certified advisor on Nasdaq First North Growth Market and can be reached at ca@vhcorp.seor +46 (0) 40 200 250.